Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Functional Variant rs4442975 Modulating FOXA1 Binding Affinity Can Influence Bone Marrow Suppression during Neoadjuvant Chemotherapy for Luminal A Type Breast Cancer.
|
30881995 |
2019 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The analysis revealed already well-established associations with XBP1 and FOXA1, but also identified a strong association with CT62, a potential immunotherapeutic target with few previous associations with breast cancer.
|
30760519 |
2019 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This is in line with other studies suggesting these SNPs as risk-associated polymorphisms which may lead to a change in the affinity of FOXA1, as a distal enhancer, to <i>TOX3</i> and thus change in <i>TOX3</i> expression, which can eventually affect the risk of breast cancer.
|
31338012 |
2019 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer.
|
31562808 |
2019 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer.
|
31826955 |
2019 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Altered FOXA1 levels contribute to endocrine-resistant breast cancer, where it maintains ER-chromatin interactions, even in contexts in which cells are refractory to ER-targeted drugs.
|
30840881 |
2019 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.
|
31644911 |
2019 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Genetic ablation of mammary ducts through foxa1 prevents breast cancer occurrence.
|
30906639 |
2019 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overall, our results indicate that FOXA1 could be a useful biomarker to predict prognosis in breast cancer patients.
|
30941644 |
2019 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
FOXA1 was reported to facilitate or reprogram ERα binding, thus playing a key function in breast cancer progression.
|
31029427 |
2019 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Breast cancer metastases (n = 164) from various anatomical sites were retrospectively analyzed by immunohistochemistry for FOXA1, Nestin and GATA3 expression.
|
30819139 |
2019 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Further, we demonstrated that FOXA1 attenuation was involved in transcriptional downregulation of proapoptotic Bim and thus suppressed breast cancer cell apoptosis.
|
30793308 |
2019 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ultrasound assisted gene and photodynamic synergistic therapy with multifunctional FOXA1-siRNA loaded porphyrin microbubbles for enhancing therapeutic efficacy for breast cancer.
|
29758547 |
2018 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome.
|
29972720 |
2018 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Here in this study, we aimed to identify which are the proteins that could potentially control FOXA1 function in breast cancer cell lines expressing different molecular markers.
|
30572598 |
2018 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
It was found that forkhead box protein A1 (FOXA1) is abnormally expressed in various tumors, such as breast cancer, ovarian cancer, and is closely related to tumorigenesis.
|
30468461 |
2018 |
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Biological assays indicated that the germline G>T variation at rs6506689 creates a FOXA1-binding site and up-regulates the expression of RAB31, thus playing an important role in the development of BC.
|
30182384 |
2018 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results suggest that miR-132 and FOXA1 may be potential biomarkers or therapeutic targets in breast cancer.
|
28816236 |
2018 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In this study, we determined the impact of OGT on expression of EZH2 target genes FOXA1 and FOXC1, that are involved in breast cancer progression.
|
29864144 |
2018 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical expression of AR and FOXA1 was evaluated on 479 consecutive BC, with complete clinical-pathological and follow up data.
|
29970021 |
2018 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Stable expression of FOXA1, but not ERα, reduced the expression of <i>IL6</i> in the FOXA1- and ERα-negative breast cancer MDA-MB-231 cells and TAM-R cells, without affecting the activation of the NF-κB signaling pathways.
|
28270510 |
2017 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
FOXA1, a known driver of hormone-receptor positive breast cancer, harbours a mutational hotspot in its promoter leading to overexpression through increased E2F binding.
|
28658208 |
2017 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Forkhead box A1 (FOXA1), a transcription factor, plays a crucial role in breast cancer and has been predicted as a target of miR-204.
|
28534958 |
2017 |
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Elevated <i>FOXA1</i> expression in BC also facilitates hormone responsiveness in estrogen receptor (<i>ESR</i>)-positive BC.
|
28789340 |
2017 |
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In contrast, constitutive (MYC, TBX3) and signal-induced (TP53, FOXA1) DB-TFs that do not mediate default repression are directly altered in breast cancer.
|
28215225 |
2017 |